Influenza vaccination in patients with pulmonary sarcoidosis: Efficacy and safety

Influenza and other Respiratory Viruses

Volumn 6, Issue 2, 2012, Pages 136-141

  Tavana, Sasan ^a   Argani, Hassan ^a   Gholamin, Sharareh ^a,b   Razavi, Seyed Mostafa ^a   Keshtkar Jahromi, Marzieh ^a   Talebian, Amir S ^a   Moghaddam, Keivan G ^c   Sepehri, Zahra ^a   Azad, Talat M ^d   Keshtkar Jahromi, Maryam ^a,e  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

Influenza; Sarcoidosis; Vaccination

Indexed keywords

CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; INFLUENZA VACCINE; VIRUS ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESIDUAL VOLUME; SARCOIDOSIS; SEROLOGY; SEX DIFFERENCE;

ADULT; ANTIBODIES, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SARCOIDOSIS, PULMONARY; VACCINATION;

EID: 84857038921     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00290.x     Document Type: Article

References (30)

1. Dempsey OJ, Paterson EW, Kerr KM, Denison AR. Sarcoidosis. BMJ 2009; 339:620-625.
2. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999; 14:735-737.
3. Marcoval J, Mañá J. Specific (granulomatous) oral lesions of sarcoidosis: report of two cases. Med Oral Patol Oral Cir Bucal 2010; 15:e456-e458.
4. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-1234.
5. Belfer MH, Stevens RW. Sarcoidosis: a primary care review. Am Fam Physician 1998; 58:2041-2050, 2055-6.
6. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12:716-738.
7. Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31:390-403.
8. James DG, Neville E, Walker A. Immunology of sarcoidosis. Am J Med 1975; 59:388-394.
9. Pasquali J, Godin D, Urlacher A, Pelletier A, Pauli G, Storck D. Abnormalities of in vitro responses to polyclonal activation of peripheral blood lymphocytes in patients with active sarcoidosis. Eur J Clin Invest 1985; 15:82-88.
10. Byrne EB, Evans AS, Fouts DW, Israel HL. A seroepidemiological study of Epstein-Barr virus and other viral antigens in sarcoidosis. Am J Epidemiol 1973; 97:355-363.
11. Majer RV, Green PJ. The immune response in sarcoidosis. Lancet 1987; 2:195-196.
12. Katz P, Fauci A. Inhibition of polyclonal B cell activation by suppressor monocytes in patients with sarcoidosis. Clin Exp Immunol 1978; 32:554-562.
13. Nosal GJ. Vaccination and autoimmunity. J Autoimmun 2000; 14:15-22.
14. Aron-Maor A, Shoenfeld Y. Vaccination and autoimmunity; in Shoenfeld Y, Rose NR (eds): Infection and autoimmunity. Amsterdam: Elsevier BV, 2004; 105-116.
15. Herron A, Dettleff G, Hixon B et al. Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA 1979; 242:53-56.
16. Mert A, Bilir M, Ozaras R, Tabak F, Karayel T, Senturk H. Results of Hepatitis B Vaccination in sarcoidosis. Respiration 2000; 67:543-545.
17. Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. J Asthma 2007; 44:817-822.
18. Bansal AS, Bruce J, Hogan PG, Allen RK. An assessment of peripheral immunity in patients with sarcoidosis using measurements of serum vitamin D3, cytokines and soluble CD23. Clin Exp Immunol 1997; 110:92-97.
19. Wat D, Gelder C, Hibbitts S et al. Is there a role for influenza vaccination in cystic fibrosis? J Cyst Fibros 2008; 7:85-88.
20. Brundage JF. Cases and deaths during influenza pandemics in the United States. Am J Prev Med 2006; 31:252-256.
21. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50-64 and 65 and older. Am J Prev Med 2006; 31:72-79.
22. Note for guidance on harmonisation of requirements for influenza vaccines. Committee for Proprietary Medicinal Products (CPMP); 1997. [].
23. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009; 55:649-660.
24. La Gruta NL, Turner SJ, Doherty PC. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J Immunol 2004; 172:5553-5560.
25. Nalbandian G, Kovats S. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol Res 2005; 31:91-106.
26. Eyries M, Michaud A, Deinum J et al. Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region. J Biol Chem 2001; 276:5525-5532.
27. Kramers C, Danilov SM, Deinum J et al. Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease. Circulation 2001; 104:1236-1240.
28. Nesterovitch AB, Hogarth KD, Adarichev VA et al. Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. PLoS ONE 2009; 4:e8282.
29. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120:102-108.
30. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006; 13:373-375.